Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 765, Issue -, Pages 86-93Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2015.08.017
Keywords
Iron overload cardiomyopathy; Iron chelator; Deferoxamine; Deferiprone; Deferasirox; Antioxidant
Categories
Funding
- NSTDA Research Chair Grant from the National Science and Technology Development Agency Thailand
- Thailand Research Fund [BRG5780016, TRG5780002]
- Royal Golden Jubilee PhD program
- Chiang Mai University Center of Excellence Award
- Faculty of Medicine Chiang Mai University Fund
Ask authors/readers for more resources
Iron overload cardiomyopathy is the major cause of death in transfusion-dependent thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators, or the combination of an iron chelator with antioxidant(s) are effective in diminishing myocardial iron deposition and attenuating cardiac dysfunction. This review comprehensively summarizes basic and clinical reports on the therapeutic efficacy of combined iron chelators, or the combination of an iron chelator with antioxidant(s) on the heart. Promising benefits of these treatments in preventing cardiac dysfunction due to iron overload could provide extensive insight into future therapeutic strategies for better treatment and prevention of cardiomyopathy in TDT patients. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available